Mereo BioPharma Group plc
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
MREO$0.28+0.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of shareholders’ equity
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Ordinary shares · Treasury shares · Additionalpaid-in · Accumulatedothercomprehensive · Accumulated · Totalshareholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Cost | Shares | Cost | capital | (loss)/income | deficit | equity | |
| Balance, December 31, 2022 | 624,928,519 | $2,478 | 1,003,030 | $(1,335) | $476,521 | $(21,687) | $(404,575) | $51,402 |
| Net loss | — | — | — | — | — | — | (29,466) | (29,466) |
| Foreign currency translation adjustments | — | — | — | — | — | 4,202 | — | 4,202 |
| Share-based compensation | — | — | — | — | 4,924 | — | — | 4,924 |
| Exercise of share options | — | — | (79,630) | 105 | (105) | — | — | — |
| Delivery of shares on vesting of deferred restricted stock units | 501,380 | 3 | — | — | — | — | — | 3 |
| Issuance of shares, net of discount | 48,367,095 | 186 | — | — | 11,284 | — | — | 11,470 |
| Conversion of convertible loan note | 27,420,095 | 108 | — | — | (6,569) | — | 14,411 | 7,950 |
| Issuance of warrants | — | — | — | — | 52 | — | — | 52 |
| Balance, December 31, 2023 | 701,217,089 | $2,775 | 923,400 | $(1,230) | $486,107 | $(17,485) | $(419,630) | $50,537 |
| Net loss | — | — | — | — | — | — | (43,253) | (43,253) |
| Foreign currency translation adjustments | — | — | — | — | — | (1,364) | — | (1,364) |
| Share-based compensation | — | — | — | — | 7,390 | — | — | 7,390 |
| Exercise of share options | 2,685,420 | 11 | (210,485) | 280 | (299) | — | — | (8) |
| Delivery of shares on vesting of restricted stock units | 433,880 | 2 | (712,915) | 950 | (953) | — | — | (1) |
| Delivery of shares on vesting of performance based restricted stock units | 6,690,755 | 25 | — | — | (67) | — | — | (42) |
| Issuance of shares, net of discount | 64,700,890 | 246 | — | — | 48,503 | — | — | 48,749 |
| Transaction costs on issuance of shares | — | — | — | — | (1,039) | — | — | (1,039) |
| Balance, December 31, 2024 | 775,728,034 | $3,059 | — | $— | $539,642 | $(18,849) | $(462,883) | $60,969 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.